AI-biotech Terray emerges with $60M and a solution for data problems in drug R&D
Terray Therapeutics uses tiny microarrays to test molecules against targets of interest, then applies artificial intelligence to build large chemical datasets. The startup’s Series A financing will support R&D initially in immunology; the first Terray molecule is expected to reach the clinic in 18 months.